<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01464060</url>
  </required_header>
  <id_info>
    <org_study_id>INHIBRICON14</org_study_id>
    <nct_id>NCT01464060</nct_id>
  </id_info>
  <brief_title>14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication</brief_title>
  <official_title>Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple &quot;Hybrid&quot; and &quot;Concomitant&quot; Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Infante, Javier Molina, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Infante, Javier Molina, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Helicobacter pylori (H. pylori) infects approximately 50% of the adult population and is well
      recognized as the main cause of gastritis, peptic ulcer disease and gastric cancer. The cure
      of the H. pylori infection prevents recurrence of duodenal and gastric ulcer and improves
      dyspepsia in a significant proportion of cases, so it is cost-effective.

      Eradication therapy has changed over time. Recent meta-analyses have that the current global
      eradication rate after standard triple therapy (STT) is less than 80%. Several European
      studies have found even lower eradication rates, with 35-40% of cases resulting in treatment
      failure, probably due to increased resistance to antibiotics in many geographical areas,
      principally to clarithromycin. The usually recommended pattern in the American and European
      (Maastricht III) consensus conferences from 2007 has traditionally been triple therapy,
      composed by the combination of 2 antibiotics (clarithromycin plus amoxicillin or
      metronidazole) and a proton pump inhibitor (PPI) for 7-14 days. However, triple therapy was
      discouraged in settings with high rates of clarithromycin resistance (15-20%) and, as such,
      new strategies in order to improve the efficacy of first-line treatments are required.
      Treatment failure increases antibiotic resistant strains, leads to a second treatment and a
      new diagnostic test to confirm eradication. Unfortunately, it remains unknown whether there
      is room for improvement in these geographical areas using clarithromycin-containing therapies
      or switching to bismuth quadruple therapy should be followed instead.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Justification of the study:

      Several non-bismuth quadruple clarithromycin-containing regimens have raised over the last
      decade aiming to substitute standard triple therapy (STT) for first-line H. pylori
      eradication therapy. Sequential therapy, introduced in Italy, involves a 5-day induction
      phase with dual therapy (a PPI every 12 hours and amoxicillin 1g every 12 hours), followed
      immediately by triple therapy for 5 days with a PPI every 12 hours, metronidazole 500 mg
      every 12 hours and clarithromycin 500 mg every 12 hours. 10-day sequential therapy proved
      more effectiveness than STT with excellent treatment compliance and minimal side effects.
      However, the efficacy of sequential therapy seems to be notably impaired by clarithromycin
      resistance and dual clarithromycin and metronidazole resistance, which is becoming a common
      scenario in developed countries.

      Other interesting and resurfaced therapeutic alternative is the non-bismuth quadruple therapy
      (NBQT), also called &quot;concomitant&quot; therapy, which includes a PPI, amoxicillin, clarithromycin
      and a nitroimidazole, all drugs given concurrently and twice daily. It has also demonstrated
      its superiority over STT and it could be potential replacement for STT as first-line regimen.
      However, NBQT might have several advantages over sequential therapy, namely, less complexity
      for both the patient and the physician, twice the duration of all prescribed antibiotics, a
      proper validation process worldwide and a higher efficacy over sequential therapy for both
      clarithromycin and dual-resistant H. pylori. Finally, another recent innovation is the 14-day
      quadruple clarithromycin-based regimen, so-called the sequential-concomitant &quot;hybrid&quot;
      therapy, which involves PPI and amoxicillin for 7 days plus a 7-day course of NBQT.
      Outstanding cure rates close to 100% have been recently reported using this scheme, thereby
      requiring further consideration.

      Therefore it is necessary to make a controlled clinical trial to directly compare NBQT
      &quot;hybrid&quot; versus &quot;concomitant&quot; therapy in settings with documented high clarithromycin
      resistance rates. In order to maximize the efficacy of eradication regimens, it would be
      necessary to extend duration to 14 days and using high-dose PPI (omeprazole 40 mg bid). The
      results of this study will conclude whether there is still room for clarithromycin-containing
      regimens in H. pylori eradication even in settings with high antibiotic resistance rates.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&quot;Intention to treat&quot; eradication rates</measure>
    <time_frame>1 year</time_frame>
    <description>&quot;Intention-to-treat&quot; eradication of infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>&quot; Per protocol&quot; eradication rate</measure>
    <time_frame>1 year</time_frame>
    <description>&quot; Per protocol&quot; eradication of the infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment compliance</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>&quot;Hybrid&quot; therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Concomitant&quot; therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPI, amoxicillin, metronidazole and clarithromycin</intervention_name>
    <description>Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.</description>
    <arm_group_label>&quot;Hybrid&quot; therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPI, amoxicillin, metronidazole and clarithromycin</intervention_name>
    <description>Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h</description>
    <arm_group_label>&quot;Concomitant&quot; therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with dyspepsia or peptic gastroduodenal ulcer for whom eradication treatment
             is indicated.

          -  Requirement of confirmation of the diagnosis of H. pylori infection by at least one
             positive test out of the following: breath test, histology, rapid urease test or
             culture.

        Exclusion Criteria:

          -  Age less than 18 years.

          -  Advanced chronic disease or any other pathology that prevents attending controls and
             follow up.

          -  Allergy to any of the antibiotics in the treatment.

          -  Previous gastric surgery

          -  Pregnancy and lactation.

          -  History of alcohol or drug abuse.

          -  Previous eradication treatment.

          -  Consumption of antibiotics or bismuth salts during the last 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Molina-Infante, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Pedro de Alcantara, Caceres, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Javier Molina-Infante, MD</last_name>
    <phone>0034627430248</phone>
    <email>xavi_molina@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Romano, MD,PhD</last_name>
      <email>marco.romano@unina2.it</email>
    </contact>
    <investigator>
      <last_name>Marco Romano</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Cuomo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Riccardo Marmo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerardo Nardone</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Lamanda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Merida</name>
      <address>
        <city>Merida</city>
        <state>Badajoz</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liliana Pozzati, MD</last_name>
      <email>santelmo0054@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Liliana Pozzati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Gata-Cuadrado</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Puerto</name>
      <address>
        <city>Plasencia</city>
        <state>Caceres</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena G Abadia</last_name>
      <email>elenagabadia@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Elena G Abadia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Molina-Infante, MD</last_name>
      <email>xavi_molina@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Javier Molina-Infante, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Belen Perez-Gallardo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Fernandez-Bermejo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007 Jun;56(6):772-81. Epub 2006 Dec 14.</citation>
    <PMID>17170018</PMID>
  </reference>
  <reference>
    <citation>Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007 Aug;102(8):1808-25. Epub 2007 Jun 29.</citation>
    <PMID>17608775</PMID>
  </reference>
  <reference>
    <citation>Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008 Jun;5(6):321-31. doi: 10.1038/ncpgasthep1138. Epub 2008 Apr 29. Review.</citation>
    <PMID>18446147</PMID>
  </reference>
  <reference>
    <citation>Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004 Sep;53(9):1374-84. Review.</citation>
    <PMID>15306603</PMID>
  </reference>
  <reference>
    <citation>Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010 Aug;59(8):1143-53. doi: 10.1136/gut.2009.192757. Epub 2010 Jun 4. Review.</citation>
    <PMID>20525969</PMID>
  </reference>
  <reference>
    <citation>Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007 Oct;56(10):1353-7. Epub 2007 Jun 12. Review.</citation>
    <PMID>17566020</PMID>
  </reference>
  <reference>
    <citation>Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med. 2008 Jun 17;148(12):923-31. Epub 2008 May 19. Erratum in: Ann Intern Med. 2008 Sep 16;149(6):439.</citation>
    <PMID>18490667</PMID>
  </reference>
  <reference>
    <citation>Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther. 2009 Feb;34(1):41-53. doi: 10.1111/j.1365-2710.2008.00969.x.</citation>
    <PMID>19125902</PMID>
  </reference>
  <reference>
    <citation>Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol. 2009 Dec;104(12):3069-79; quiz 1080. doi: 10.1038/ajg.2009.555. Epub 2009 Oct 20. Review.</citation>
    <PMID>19844205</PMID>
  </reference>
  <reference>
    <citation>Gisbert JP, Calvet X, O'Connor A, Mégraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010 May-Jun;44(5):313-25. doi: 10.1097/MCG.0b013e3181c8a1a3. Review.</citation>
    <PMID>20054285</PMID>
  </reference>
  <reference>
    <citation>Gisbert JP, Nyssen OP, McNicholl A, et al. Meta-analysis of sequential vs. standard triple therapy for Helicobacter pylori eradication. Helicobacter 2011;16 (Suppl 1):131.</citation>
  </reference>
  <reference>
    <citation>Prieto-Jimenez CA, Cardenas VM, Fischbach LA, Mulla ZD, Rivera JO, Dominguez DC, Graham DY, Ortiz M. Double-blind randomized trial of quadruple sequential Helicobacter pylori eradication therapy in asymptomatic infected children in El Paso, Texas. J Pediatr Gastroenterol Nutr. 2011 Mar;52(3):319-25. doi: 10.1097/MPG.0b013e318206870e.</citation>
    <PMID>21336156</PMID>
  </reference>
  <reference>
    <citation>Bontems P, Kalach N, Oderda G, Salame A, Muyshont L, Miendje DY, Raymond J, Cadranel S, Scaillon M. Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2011 Dec;53(6):646-50. doi: 10.1097/MPG.0b013e318229c769.</citation>
    <PMID>21701406</PMID>
  </reference>
  <reference>
    <citation>Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, Hernandez-Alonso M, Vinagre G, Dueñas C, Mateos-Rodriguez JM, Gonzalez-Garcia G, Abadia EG, Gisbert JP. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2010 May;31(10):1077-84. doi: 10.1111/j.1365-2036.2010.04274.x. Epub 2010 Feb 20.</citation>
    <PMID>20180787</PMID>
  </reference>
  <reference>
    <citation>Choi WH, Park DI, Oh SJ, Baek YH, Hong CH, Hong EJ, Song MJ, Park SK, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI. [Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea]. Korean J Gastroenterol. 2008 May;51(5):280-4. Korean.</citation>
    <PMID>18516011</PMID>
  </reference>
  <reference>
    <citation>Remes-Troche JM, Alarcon-Rivera G, Ramos-de la Medina A, et al. Sequential therapy vs standard triple therapy as treatment of Helicobacter pylori infection. A prospective, randomized, parallel-group, open-label study in Mexico. Gastroenterology 2010;138:S-336.</citation>
  </reference>
  <reference>
    <citation>Romano M, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, Sica M, Rocco A, Salerno R, Marmo R, Federico A, Nardone G. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut. 2010 Nov;59(11):1465-70. doi: 10.1136/gut.2010.215350.</citation>
    <PMID>20947881</PMID>
  </reference>
  <reference>
    <citation>Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol. 2010 Jan;8(1):36-41.e1. doi: 10.1016/j.cgh.2009.09.030. Epub 2009 Oct 3.</citation>
    <PMID>19804842</PMID>
  </reference>
  <reference>
    <citation>Sirimontaporn N, Thong-Ngam D, Tumwasorn S, Mahachai V. Ten-day sequential therapy of Helicobacter pylori infection in Thailand. Am J Gastroenterol. 2010 May;105(5):1071-5. doi: 10.1038/ajg.2009.708. Epub 2009 Dec 15.</citation>
    <PMID>20010919</PMID>
  </reference>
  <reference>
    <citation>Mahachai V, Sirimontaporn N, Tumwasorn S, Thong-Ngam D, Vilaichone RK. Sequential therapy in clarithromycin-sensitive and -resistant Helicobacter pylori based on polymerase chain reaction molecular test. J Gastroenterol Hepatol. 2011 May;26(5):825-8. doi: 10.1111/j.1440-1746.2011.06660.x.</citation>
    <PMID>21251064</PMID>
  </reference>
  <reference>
    <citation>Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med. 2007 Apr 17;146(8):556-63.</citation>
    <PMID>17438314</PMID>
  </reference>
  <reference>
    <citation>Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther. 2011 Sep;34(6):604-17. doi: 10.1111/j.1365-2036.2011.04770.x. Epub 2011 Jul 11. Review.</citation>
    <PMID>21745241</PMID>
  </reference>
  <reference>
    <citation>Molina-Infante J, Pazos-Pacheco MC, Perez-Gallardo B, et al. Efficacy of non-bismuth quadruple &quot;concomitant&quot; therapy for H. pylori infection in a setting with high clarithromycin resistance. Gastroenterology 2011; Suppl 1:S-880.</citation>
  </reference>
  <reference>
    <citation>Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011 Apr;16(2):139-45. doi: 10.1111/j.1523-5378.2011.00828.x.</citation>
    <PMID>21435092</PMID>
  </reference>
  <reference>
    <citation>Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F; Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011 Mar 12;377(9769):905-13. doi: 10.1016/S0140-6736(11)60020-2. Epub 2011 Feb 21. Erratum in: Lancet. 2011 Nov 19;378(9805):1778. Dosage error in article text.</citation>
    <PMID>21345487</PMID>
  </reference>
  <reference>
    <citation>Dore MP, Farina V, Cuccu M, Mameli L, Massarelli G, Graham DY. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter. 2011 Aug;16(4):295-300. doi: 10.1111/j.1523-5378.2011.00857.x.</citation>
    <PMID>21762269</PMID>
  </reference>
  <reference>
    <citation>Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008 Oct 1;28(7):868-77. doi: 10.1111/j.1365-2036.2008.03807.x. Epub 2008 Jul 17.</citation>
    <PMID>18644011</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>October 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2011</study_first_posted>
  <last_update_submitted>December 27, 2012</last_update_submitted>
  <last_update_submitted_qc>December 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Quadruple therapy</keyword>
  <keyword>Clarithromycin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 14, 2017</submitted>
    <returned>April 24, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

